Experimental Hematology
Volume 38, Issue 2 , Pages 71-81 , February 2010

Loss of SIMPL compromises TNF-α-dependent survival of hematopoietic progenitors

  • Eric A. Benson

      Affiliations

    • Department of Biochemistry and Molecular Biology, Indiana University School of Medicine, Indianapolis, Ind., USA
    • ,
  • Mark G. Goebl

      Affiliations

    • Department of Biochemistry and Molecular Biology, Indiana University School of Medicine, Indianapolis, Ind., USA
    • ,
  • Feng-Chun Yang

      Affiliations

    • Department of Pediatrics and the Herman B Wells Center for Pediatric Research, Indiana University School of Medicine, Indianapolis, Ind., USA
    • ,
  • Reuben Kapur

      Affiliations

    • Department of Pediatrics and the Herman B Wells Center for Pediatric Research, Indiana University School of Medicine, Indianapolis, Ind., USA
    • ,
  • Jeanette McClintick

      Affiliations

    • Department of Biochemistry and Molecular Biology, Indiana University School of Medicine, Indianapolis, Ind., USA
    • ,
  • Sonal Sanghani

      Affiliations

    • Department of Biochemistry and Molecular Biology, Indiana University School of Medicine, Indianapolis, Ind., USA
    • ,
  • D. Wade Clapp

      Affiliations

    • Department of Pediatrics and the Herman B Wells Center for Pediatric Research, Indiana University School of Medicine, Indianapolis, Ind., USA
    • ,
  • Maureen A. Harrington

      Affiliations

    • Department of Biochemistry and Molecular Biology, Indiana University School of Medicine, Indianapolis, Ind., USA
    • Corresponding Author InformationOffprint requests to: Dr. Maureen A. Harrington, Ph.D., Department of Biochemistry and Molecular Biology, Indiana University School of Medicine, Indianapolis, IN 46202-5122

Received 5 October 2009 ,Revised 14 November 2009 ,Accepted 16 November 2009.

References 

  1. Dybedal I, Bryder D, Fossum A, Rusten LS, Jacobsen SE. Tumor necrosis factor (TNF)-mediated activation of the p55 TNF receptor negatively regulates maintenance of cycling reconstituting human hematopoietic stem cells. Blood. 2001;98:1782–1791
  2. Zhang Y, Harada A, Bluethmann H, et al. Tumor necrosis factor (TNF) is a physiologic regulator of hematopoietic progenitor cells: increase of early hematopoietic progenitor cells in TNF receptor p55-deficient mice in vivo and potent inhibition of progenitor cell proliferation by TNF alpha in vitro. Blood. 1995;86:2930–2937
  3. Slordal L, Warren DJ, Moore MA. Protective effects of tumor necrosis factor on murine hematopoiesis during cycle-specific cytotoxic chemotherapy. Cancer Res. 1990;50:4216–4220
  4. Warren DJ, Slordal L, Moore MA. Tumor-necrosis factor induces cell cycle arrest in multipotential hematopoietic stem cells: a possible radioprotective mechanism. Eur J Haematol. 1990;45:158–163
  5. Caux C, Favre C, Saeland S, et al. Potentiation of early hematopoiesis by tumor necrosis factor-alpha is followed by inhibition of granulopoietic differentiation and proliferation. Blood. 1991;78:635–644
  6. Cross A, Moots RJ, Edwards SW. The dual effects of TNFalpha on neutrophil apoptosis are mediated via differential effects on expression of Mcl-1 and Bfl-1. Blood. 2008;111:878–884
  7. Fluck J, Schachtschneider S, Abken H. Autocrine proliferating B cells are susceptible to terminal differentiation and apoptosis. Cell Death Differ. 1997;4:824–833
  8. Zheng L, Fisher G, Miller RE, Peschon J, Lynch DH, Lenardo MJ. Induction of apoptosis in mature T cells by tumour necrosis factor. Nature. 1995;377:348–351
  9. Ershler MA, Nifontova IN, Olshanskaya YV, Todria TV, Chertkov JL, Drize NJ. Neoplastic transformation is not the cause of extremely long (more than 100 weeks) hematopoiesis maintenance of long-term bone marrow culture from TNF-deficient mice. Hematol J. 2003;4:74–77
  10. Drutskaya MS, Ortiz M, Liepinsh DJ, Kuprash DV, Nedospasov SA, Keller JR. Inhibitory effects of tumor necrosis factor on hematopoiesis seen in vitro are translated to increased numbers of both committed and multipotent progenitors in TNF-deficient mice. Exp Hematol. 2005;33:1348–1356
  11. Rebel VI, Hartnett S, Hill GR, Lazo-Kallanian SB, Ferrara JL, Sieff CA. Essential role for the p55 tumor necrosis factor receptor in regulating hematopoiesis at a stem cell level. J Exp Med. 1999;190:1493–1504
  12. Licastro F, Candore G, Lio D, et al. Innate immunity and inflammation in ageing: a key for understanding age-related diseases. Immun Ageing. 2005;2:8
  13. Manicourt DH, Triki R, Fukuda K, et al. Levels of circulating tumor necrosis factor alpha and interleukin-6 in patients with rheumatoid arthritis. Relationship to serum levels of hyaluronan and antigenic keratan sulfate. Arthritis Rheum. 1993;36:490–499
  14. Rayet B, Gelinas C. Aberrant rel/nfkb genes and activity in human cancer. Oncogene. 1999;18:6938–6947
  15. Lindemann A, Ludwig WD, Oster W, Mertelsmann R, Herrmann F. High-level secretion of tumor necrosis factor-alpha contributes to hematopoietic failure in hairy cell leukemia. Blood. 1989;73:880–884
  16. Bojarska-Junak A, Rolinski J, Wasik-Szczepaneko E, Kaluzny Z, Dmoszynska A. Intracellular tumor necrosis factor production by T- and B-cells in B-cell chronic lymphocytic leukemia. Haematologica. 2002;87:490–499
  17. Iversen PO, Woldbaek PR, Tonnessen T, Christensen G. Decreased hematopoiesis in bone marrow of mice with congestive heart failure. Am J Physiol. 2002;282:R166–R172
  18. Sawanobori M, Yamaguchi S, Hasegawa M, et al. Expression of TNF receptors and related signaling molecules in the bone marrow from patients with myelodysplastic syndromes. Leuk Res. 2003;27:583–591
  19. Sarzi-Puttini P, Atzeni F, Shoenfeld Y, Ferraccioli G. TNF-alpha, rheumatoid arthritis, and heart failure: a rheumatological dilemma. Autoimmun Rev. 2005;4:153–161
  20. Grell M, Wajant H, Zimmermann G, Scheurich P. The type 1 receptor (CD120a) is the high-affinity receptor for soluble tumor necrosis factor. Proc Natl Acad Sci U S A. 1998;95:570–575
  21. Kalb A, Bluethmann H, Moore MW, Lesslauer W. Tumor necrosis factor receptors (Tnfr) in mouse fibroblasts deficient in Tnfr1 or Tnfr2 are signaling competent and activate the mitogen-activated protein kinase pathway with differential kinetics. J Biol Chem. 1996;271:28097–28104
  22. Aggarwal BB. Signalling pathways of the TNF superfamily: a double-edged sword. Nature Rev Immunol. 2003;3:745–756
  23. Vig E, Green M, Liu Y, et al. SIMPL is a tumor necrosis factor-specific regulator of nuclear factor-kappaB activity. J Biol Chem. 2001;276:7859–7866
  24. Kwon H-J, Breese EH, Vig-Varga E, et al. Tumor necrosis factor alpha induction of NF-kappaB requires the novel coactivator SIMPL. Mol Cell Biol. 2004;24:9317–9326
  25. Haneline LS, Gobbett TA, Ramani R, et al. Loss of FancC function results in decreased hematopoietic stem cell repopulating ability. Blood. 1999;94:1–8
  26. Zar JH. Biostatistical analysis. 4th ed.. Upper Saddle River, NJ: Prentice Hall; 1999;
  27. Li W, Johnson SA, Shelley WC, Yoder MC. Hematopoietic stem cell repopulating ability can be maintained in vitro by some primary endothelial cells. Exp Hematol. 2004;32:1226–1237
  28. Jacobsen FW, Dubois CM, Rusten LS, Veiby OP, Jacobsen SE. Inhibition of stem cell factor-induced proliferation of primitive murine hematopoietic progenitor cells signaled through the 75-kilodalton tumor necrosis factor receptor. Regulation of c-kit and p53 expression. J Immunol. 1995;154:3732–3741
  29. Jacobsen FW, Rothe M, Rusten L, et al. Role of the 75-kDa tumor necrosis factor receptor: inhibition of early hematopoiesis. Proc Natl Acad Sci U S A. 1994;91:10695–10699
  30. Broxmeyer HE. Suppressor cytokines and regulation of myelopoiesis. Biology and possible clinical uses. Am J Pediatr Hematol Oncol. 1992;14:22–30
  31. Wallays G, Ceuppens JL. Human T lymphocyte activation by pokeweed mitogen induces production of TNF-alpha and GM-CSF and helper signaling by IL-1 and IL-6 results in IL-2-dependent T cell growth. Eur Cytokine Netw. 1993;4:269–277
  32. Metcalf D, Johnson GR. Production by spleen and lymph node cells of conditioned medium with erythroid and other hemopoietic colony-stimulating activity. J Cell Physiol. 1978;96:31–42
  33. Ito Y, Tsurudome M, Yamada A, Hishiyama M. Interferon induction in mouse spleen cells by mitogenic and nonmitogenic lectins. J Immunol. 1984;132:2440–2444
  34. Funaba M, Nakaya K, Ikeda T, Murakami M, Tsuchida K, Sugino H. Requirement of Smad3 for mast cell growth. Cell Immunol. 2006;240:47–52
  35. Tartaglia LA, Pennica D, Goeddel DV. Ligand passing: the 75-kDa tumor necrosis factor (TNF) receptor recruits TNF for signaling by the 55-kDa TNF receptor. J Biol Chem. 1993;268:18542–18548
  36. Till A, Rosenstiel P, Krippner-Heidenreich A, et al. The Met-196 → Arg variation of human tumor necrosis factor receptor 2 (TNFR2) affects TNF-alpha-induced apoptosis by impaired NF-kappaB signaling and target gene expression. J Biol Chem. 2005;280:5994–6004
  37. McDade TP, Perugini RA, Vittimberga FJ, Callery MP. Ubiquitin-proteasome inhibition enhances apoptosis of human pancreatic cancer cells. Surgery. 1999;126:371–377
  38. Batra RK, Guttridge DC, Brenner DA, Dubinett SM, Baldwin AS, Boucher RC. IkappaBalpha gene transfer is cytotoxic to squamous-cell lung cancer cells and sensitizes them to tumor necrosis factor-alpha-mediated cell death. Am J Respir Cell Mol Biol. 1999;21:238–245
  39. Beg AA, Sha WC, Bronson RT, Ghosh S, Baltimore D. Embryonic lethality and liver degeneration in mice lacking the RelA component of NF-kappa B. Nature. 1995;376:167–170
  40. Rosenfeld ME, Prichard L, Shiojiri N, Fausto N. Prevention of hepatic apoptosis and embryonic lethality in RelA/TNFR-1 double knockout mice. Am J Pathol. 2000;156:997–1007
  41. Alcamo E, Mizgerd JP, Horwitz BH, et al. Targeted mutation of TNF receptor I rescues the RelA-deficient mouse and reveals a critical role for NF-kappa B in leukocyte recruitment. J Immunol. 2001;167:1592–1600
  42. Rogers JA, Berman JW. TNF-alpha inhibits the further development of committed progenitors while stimulating multipotential progenitors in mouse long-term bone marrow cultures. J Immunol. 1994;153:4694–4703
  43. Bagby GC, Lipton JM, Sloand EM, Schiffer CA. Marrow failure. Hematology Am Soc Hematol Educ Program. 2004;318–336
  44. Gersuk GM, Beckham C, Loken MR, et al. A role for tumour necrosis factor-alpha, Fas and Fas-Ligand in marrow failure associated with myelodysplastic syndrome. Br J Haematol. 1998;103:176–188
  45. Stifter G, Heiss S, Gastl G, Tzankov A, Stauder R. Over-expression of tumor necrosis factor-alpha in bone marrow biopsies from patients with myelodysplastic syndromes: relationship to anemia and prognosis. Eur J Haematol. 2005;75:485–491
  46. Boula A, Voulgarelis M, Giannouli S, et al. Effect of cA2 anti-tumor necrosis factor-alpha antibody therapy on hematopoiesis of patients with myelodysplastic syndromes. Clin Cancer Res. 2006;12:3099–3108
  47. Teh HS, Seebaran A, Teh SJ. TNF receptor 2-deficient CD8 T cells are resistant to Fas/Fas ligand-induced cell death. J Immunol. 2000;165:4814–4821
  48. Malcovati L, Porta MG, Pascutto C, et al. Prognostic factors and life expectancy in myelodysplastic syndromes classified according to WHO criteria: a basis for clinical decision making. J Clin Oncol. 2005;23:7594–7603
  49. Guzman ML, Neering SJ, Upchurch D, et al. Nuclear factor-kappaB is constitutively activated in primitive human acute myelogenous leukemia cells. Blood. 2001;98:2301–2307
  50. Baumgartner B, Weber M, Quirling M, et al. Increased IkappaB kinase activity is associated with activated NF-kappaB in acute myeloid blasts. Leukemia. 2002;16:2062–2071
  51. Sethi G, Ahn KS, Xia D, Kurie JM, Aggarwal BB. Targeted deletion of MKK4 gene potentiates TNF-induced apoptosis through the down-regulation of NF-{kappa}B activation and NF-{kappa}B-regulated antiapoptotic gene products. J Immunol. 2007;179:1926–1933
  52. Turco MC, Romano MF, Petrella A, Bisogni R, Tassone P, Venuta S. NF-kappaB/Rel-mediated regulation of apoptosis in hematologic malignancies and normal hematopoietic progenitors. Leukemia. 2004;18:11–17
  53. Tamm I, Kornblau SM, Segall H, et al. Expression and prognostic significance of IAP-family genes in human cancers and myeloid leukemias. Clin Cancer Res. 2000;6:1796–1803

PII: S0301-472X(09)00449-4

doi: 10.1016/j.exphem.2009.11.006

Experimental Hematology
Volume 38, Issue 2 , Pages 71-81 , February 2010

Article Tools

* Image Usage & Resolution